Einige Inhalte dieser Anwendung sind momentan nicht verfügbar.
Wenn diese Situation weiterhin besteht, kontaktieren Sie uns bitte unterFeedback&Kontakt
1. (WO2018164573) VIRAL POLYPEPTIDE INHIBITORS



Haftungsausschluss Als offizielle Version gilt die auf PATENTSCOPE verfügbare Version im Bildformat (PDF). Die vorliegende Online-Version im html-Format dient als zusätzliche Nutzungshilfe. Bei der Zusammenstellung der gedruckten Unterlagen/Bilder wurde mit größter Sorgfalt vorgegangen, um die genaue und zuverlässige Darstellung der darin enthaltenen Daten zu gewährleisten. Dennoch können im Zuge der Datenübermittlung und -konvertierung sowie aufgrund der systembedingten Anwendungsgrenzen der (wahlweisen) maschinellen Übersetzung entstandene Fehler und/oder Auslassungen nicht ausgeschlossen werden. Mit dem Symbol versehene Hyperlinks verweisen auf externe Quellen, auf welche die WIPO keinen Einfluss hat. WIPO lehnt jede Haftung im Zusammenhang mit den obenstehenden Punkten ab.

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/NL2018/050137 P114435PC00
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
06 March 2018 06 March 2017
Applicant
ACADEMISCH ZIEKENHUIS LEIDEN H O D N LUMC
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
a. forming part of the international application as filed:
in the form of an Annex C/ST.25 text file.
on paper or in the form of an image file.
b. furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
c. furnished subsequent to the international filing date for the purposes of international search only:
in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2.
In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.
Additional comments:
2. Certain claims were found unsearchable
3. Unity of invention is lacking
This International Searching Authority found multiple inventions in this international application, as follows:
1. claims: 1, 2, 7, 13(completely); 5, 6, 9-12, 15(partially)
An inhibitor comprising a beta-grasp fold, wherein said fold comprises region 1 (amino acids 2-14), region 2 (amino acids 42-49), and region 3 (amino acids 62-76) of the amino acid sequence set forth in SEQ ID NO:1, wherein the inhibitor comprises one or more amino acid substitutions in said regions as compared to the amino acid sequence set forth in SEQ ID NO:1, and wherein said substitutions include an amino acid substitution of A to F at the amino acid position corresponding to 46 of SEQ ID NO: 1 and/or an amino acid substitution of E to Y at the amino acid position corresponding to 64 of SEQ ID NO: 1; the nucleic acid encoding said inhibitor, a vector expressing said nucleic acid, an in vitro cell line/non-human cell/non-human organism expressing said vector, a pharmaceutical composition comprising the inhibitor; its the use for inhibiting the biological activity of a viral protein, and its use in therapy; a method for identifying the inhibitor
2. claims: 3, 4, 8, 14(completely); 5, 6, 9-12, 15(partially)
An inhibitor comprising a beta-grasp fold, wherein said fold comprises region 1 (amino acids 2-14), region 2 (amino acids 42-49), and region 3 (amino acids 62-76) of the amino acid sequence set forth in SEQ ID NO:1, wherein the inhibitor comprises one or more amino acid substitutions in said regions as compared to the amino acid sequence set forth in SEQ ID NO:1, and wherein said substitution include an amino acid substitution of R to G at the amino acid position corresponding to 74 of SEQ ID NO: 1; the nucleic acid encoding said inhibitor, a vector expressing said nucleic acid, an in vitro cell line/non-human cell/non-human organism expressing said vector, a pharmaceutical composition comprising the inhibitor; its the use for inhibiting the biological activity of a viral protein, and its use in therapy; a method for identifying the inhibitor
1.
As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.
As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3.
As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.
No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest
The additional search fees were accompanied by the applicant’s protest and, where applicable, the payment of a protest fee.
The additional search fees were accompanied by the applicant’s protest but the applicable protest fee was not paid within the time limit specified in the invitation.
No protest accompanied the payment of additional search fees.
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No. ____________
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     A61K 38/55 (2006.01)i; A61P 31/14 (2006.01)i
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     A61K; A61P
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
EPO-Internal, WPI Data, BIOSIS, CHEM ABS Data, Sequence Search, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
X
WO 2012020289 A2 (UNIV TORONTO [CA]; SIDHU SACHDEV [CA]; BEATTY LINDA [CA]; ERNST ANDREA) 16 February 2012 (2012-02-16)
1-15
cited in the application
claims 1-2; figures 6,13,21; sequences 27,28,95,96,139
(2)
A
Mark Kemp ET AL, "Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors", "PROGRESS IN MEDICINAL CHEMISTRY.", page 149-192, 01 January 2016 (2016-01-01), NLELSEVIER, AMSTERDAM.,
XP055333853
1-15
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
WO 2012020289 A2
16 February 2012
CA 2807774 A1
EP 2603519 A2
EP 2719707 A2
EP 3366697 A1
US 2013225436 A1
WO 2012020289 A2
16 February 2012
19 June 2013
16 April 2014
29 August 2018
29 August 2013
16 February 2012
Name and mailing address of the ISA/:
European Patent Office
P.B. 5818, Patentlaan 2, 2280 HV Rijswijk,
Netherlands
Telephone No. (+31-70)340-2040
Facsimile No. (+31-70)340-3016
Date of the actual completion of the international search:
20 August 2018
Date of mailing of the international search report:
28 August 2018
Authorized officer:
Vandenbogaerde, Ann
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E